THYROCARE Thyrocare Technologies Q1 FY26 results (Apr–Jun 2025) and concall
Thyrocare Technologies Limited reported a strong Q1 FY26, with consolidated revenue growing 23% YoY, driven by robust performance in pathology, franchise, and partnership segments. The company achieved significant margin expansion, with standalone normalized EBITDA margin reaching 35%. Key operational metrics like test volumes and patient served also saw double-digit growth, supported by network expansion and strategic integrations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 177 | 166 | 187 | 193 |
| EBITDA | 48 | 42 | 57 | 58 |
| Net profit | 26 | 19 | 22 | 38 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
